Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
